Exclaimer adds UKG Ready integration as HR systems displace IT-managed directories as the source of employee data
Multimedia Update – Sweet Security Launches Sweet Attack to Debunk The Myth Before Mythos Ships
Power Synch’s Competitive Bidding Platform Delivers $329K+ in Documented Savings Across 7 Wholesale Energy Procurement Events
AVI urges the dismissal of two directors at Wacom
Euro Manganese Announces Positive Preliminary Economic Assessment
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients…
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models…
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in…
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1…
“Austin Accident Lawyer” Andrew Traub shares how his firm has helped their clients get past…
Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent…
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate…
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis)…
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and…
— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed…
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and…
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and…
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib…
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral…
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose…
AFM13 in combination with NK cells shows very high overall and complete response rates in…
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in…
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium,…
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the…
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured…